Trevi Health Ventures

US HealthVest is an innovative behavioral healthcare firm that has redefined the psychiatric hospital space. De novo strategies and acquisitions of operating facilities with unrealized potential are the core of the US HealthVest business model. Each facility is structured to offer multiple service lines in order to serve the needs of specific patient population groups. The senior management team of US HealthVest has successfully built psychiatric hospital businesses which were acquired by public companies. Ascend Health was founded by Richard Kresch, M.D. in 2005 and was one of the largest private psychiatric hospital providers with nine freestanding facilities and nearly 900 beds. Ascend Health was sold to Universal Health Services (NYSE: UHS) in 2012. The predecessor company, Heartland Health Developments, also focused on psychiatric care and was sold to Psychiatric Solutions in 2004.

Manhattan Labs was founded in 2008 with the goal of creating the premier service-oriented, high-quality independent clinical laboratory in the New York City metropolitan area. Combining the latest in clinical laboratory technology, personalized service, exceptional turnaround time and easy-to-access results, Manhattan Labs is continuing to elevate the standards and setting a new benchmark of service in the laboratory industry.

Paradigm Spine, LLC (Paradigm Spine) is a privately-held medical device company, engaged in the development of spinal implants for the spine and orthopedic markets. It develops non fusion spinal implants, motion preserving products and tissue sparing products. Paradigm Spine's product Coflex, an interspinous implant used in the treatment of facet arthosis and decompressive procedures. Its products are used for spinal stabilization, rebalances spinal segment and restores natural anatomical function. The company is headquartered in New York, the US. The company also focused on the development of DSS system, a minimally-invasive pedicle-screw based system, which received a European CE Mark in April 2007 and FDA market clearance in January 2008.

Small Bones Innovations (SBi) makes devices for small bones and joints, particularly focusing on trauma and arthroplasty.

Since 2005, MedAvante has provided trial sponsors with a highly trained and standardized cohort of expert Central raters to remotely perform live interviews with subjects at investigative sites via videoconferencing or telephone – and delivered conclusive outcomes in dozens of global trials.

Small Bone Innovations (SBi) specializes in the development and manufacturing of medical devices aimed at small bones and joints, with a particular emphasis on trauma and arthroplasty. The company provides a range of implants designed for various anatomical areas, including the thumb, hand, wrist, elbow, foot, and ankle. Its product offerings include implants specifically designed to treat basal joint arthritis and those intended for replacing anatomic joint surfaces. SBi's innovations focus on preserving bone structure and minimizing disruption to collateral ligament origins and insertions, as well as soft skeletal implants, thereby enhancing surgical outcomes for patients with joint-related conditions.

Optovue Corporation is an ophthalmic device company dedicated to working with eye care professionals and clinical researchers to lead the commercialization of new imaging modalities that improve diagnosis and therapy of ocular disease. Incorporated in December 2003 and located in Fremont California, Optovue was founded by pioneers of Optical Coherence Tomography to develop the next generation ophthalmic diagnosis instrument based on the Fourier-Domain OCT technology. The ultra-high speed high resolution FD-OCT provides physicians with advanced retina diagnostic capabilities that will have significant benefit for patients who have retina conditions such as macular degeneration, diabetic retinopathy, glaucoma, and other macular diseases.

Omeros is a Seattle-based commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system.

Ikonisys is transforming diagnostic medicine by enabling early, accurate and non-invasive disease detection. Through a unique combination of technology and science, Ikonisys is dedicated to helping physicians and researchers realize the promise of rare cell detection to give patients the best chance of managing their disease.